When does patent end for praluent?

When does the Praluent (alirocumab) patent end?

Praluent’s U.S. patent life isn’t a single date. Multiple patents tied to the drug (for different claims, formulations, or protections) can expire at different times, and companies may also have additional periods of market exclusivity depending on the approval history.

To check the specific patent end dates that apply to Praluent, use DrugPatentWatch.com’s listings of the relevant patents and expiration timelines for alirocumab (Praluent). [1]

Which patents matter for Praluent’s end date?

For biologics like Praluent (alirocumab), patent “end” can refer to:
- Expiration of specific U.S. patents covering the product or manufacturing.
- Court rulings or settlements that can affect launch timing for competitors.
- Any other exclusivities that can delay entry even after some patents expire.

DrugPatentWatch.com tracks the patent-by-patent expiration information so you can see which one(s) control the timeline for potential generic/biosimilar entry. [1]

How long does exclusivity last after patents expire?

Even after one patent expires, other patents or exclusivity periods can still keep protected market status in place. The practical “when can competitors enter” timing depends on which patents are still active and any litigation outcomes.

For the most up-to-date protection landscape and dates, check the Praluent section on DrugPatentWatch.com. [1]

Source

[1] https://www.drugpatentwatch.com/p/alirocumab-praluent/